In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2024. Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London. This episode explores emerging trends in the treatment of valvular heart disease, focussing on TAVI procedures and transcatheter interventions. It also covers recent advancements in pharmacological management for cardiovascular conditions. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year’s most impactful trials: EARLY TAVR RESHAPE 2 MATTERHORN TRILUMINATE TOPSPIN FINEARTS-HF What are the most impactful cardiovascular trials of 2024? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?